일회용 소모품 시장 : 제품 유형, 소재 유형, 소재 형태, 멸균 상태, 규제 분류, 용도, 최종 용도, 유통 채널별 - 세계 예측(2026-2032년)

The Single Use Consumables Market was valued at USD 5.65 billion in 2025 and is projected to grow to USD 6.20 billion in 2026, with a CAGR of 10.07%, reaching USD 11.07 billion by 2032.

Single-use consumables are redefining quality, speed, and resilience as bioprocessing pivots to flexible, compliant, digitally enabled production

Single-use consumables have moved from tactical convenience to strategic necessity across the life sciences enterprise. On the production floor, they are the backbone of flexible facilities that switch rapidly between modalities, from monoclonal antibodies to cell and gene therapies and mRNA platforms. In research and diagnostics environments, they underpin throughput, contamination control, and reproducibility. This shift coincides with heightened quality expectations from regulators and payers, a sharper spotlight on extractables and leachables, and a renewed push to regionalize supply chains after recent disruptions.

Two external forces accelerated the pivot. First, safety communications and enforcement actions around plastic syringes manufactured in China have intensified scrutiny of quality systems and supplier oversight throughout the broader single-use category. The U.S. Food and Drug Administration advised transitioning away from specific manufacturers and affirmed that non-China capacity-including domestic production-can support demand. That guidance has already nudged purchasing toward alternative sources and catalyzed domestic capacity additions by key players. Second, tariff policy has entered the operational core of decision-making. As of late 2024 and through 2025, the United States expanded and, in some cases, sharply increased Section 301 duties on selected medical products and critical inputs, with additional effective dates extending into 2026. Syringes and needles moved to a 100% rate; medical gloves will step to higher rates in 2025 and 2026; and semiconductors-vital for sensor modules and smart instrumentation-were set for a 2025 increase. Procurement, pricing, and footprint strategies are being rewritten accordingly. Against this backdrop, executives are reframing single-use portfolios around quality-by-design, compliance readiness, and modularity. The winners will be those who can standardize where it matters for reliability and cost, while preserving customization at the edges to serve novel therapies and evolving workflows. The following sections surface the most consequential shifts, policy impacts, and segmentation dynamics shaping that race.

Transformational shifts accelerate adoption: closed, sterile workflows, polymer scrutiny, regionalized supply, and smart sensors reshape single-use strategies

The landscape is undergoing a series of transformations that reach from polymer science to plant network design. On the regulatory front, the most consequential development is the trajectory of USP chapters <665> and <1665>, which were approved in 2024 with an official effective date of May 1, 2026. These chapters elevate expectations for qualification of plastic components and systems used in manufacturing, pushing suppliers and end users toward harmonized extractables and leachables strategies, rigorous material-of-construction documentation, and risk-based assessments that align with modern quality systems. In parallel, updates to <661.1> and <661.2> advance the framework for plastic materials and packaging, with December 2025 effective dates that intersect operationally with single-use assemblies and labware. While compliance anchors design, technology is redefining how single-use systems operate day to day. Integrated magnetic mixing platforms and scalable bioreactors have matured beyond proof-of-concept, supporting high-throughput buffer prep, media handling, and intensified upstream processes without sacrificing sterility or footprint efficiency. Recent releases include large-scale single-use magnetic mixing systems and expanded 500 L to 2,000 L bioreactor offerings that simplify scale-up and reduce changeover time-capabilities that are now essential for multiproduct facilities and clinical-to-commercial transitions. Concurrently, smart sensors and analytics are reshaping the value proposition. Single-use pH and dissolved oxygen sensors, complemented by digital process analytics, are moving from nice-to-have to must-have, enabling at-line and in-line visibility that supports parametric release and real-time decision-making. As semiconductors become a larger share of bill-of-materials for sensors and monitoring systems, their supply and tariff status directly influence component cost and availability-linking digital capability with trade policy in unexpected ways. Supply chain architecture is also being remapped. "In-region for region" strategies are accelerating, with manufacturers adding capacity closer to demand centers to reduce cross-border exposure and shorten lead times. Climate-aligned facilities and renewable-powered operations are increasingly built into these expansions, reflecting both corporate commitments and customer requirements for scope 3 transparency. New distribution and down-filling capabilities in Europe, expansions in North America, and selective growth in Asia signal a more balanced global footprint, even as companies retain the flexibility of global component sourcing. Cumulative impact of 2025 United States tariffs reshapes sourcing for syringes, gloves, masks, and inputs, tightening compliance and total landed costs

Tariff policy moved from background noise to a primary design constraint for U.S.-bound single-use consumables in 2025. Following the four-year review of Section 301 actions, the United States finalized a set of increases that directly affect medical products and key inputs. Syringes and needles imported from China shifted to a 100% rate effective September 27, 2024, with an exclusion for enteral syringes that runs through January 1, 2026. Rubber medical or surgical gloves are scheduled to face higher rates in stages-stepping up in 2025 and again in 2026-while selected respiratory masks move to 25% and then 50% on a defined schedule. Separately, semiconductors are set at 50% starting January 1, 2025, a change that indirectly affects single-use instruments and sensor modules. The cumulative impact is multifaceted. Direct cost inflation hits categories like syringes and certain protective equipment immediately, while indirect pressures seep in via electronics used in sensors and controls. Existing Section 301 rates of 7.5% or 25% still apply across many tariff lines covering plastic labware, assemblies, and components; the finalized notice confirms that these baseline duties continue, with the new increases layered on top for targeted lines. This creates a two-tier risk profile where some SKUs face dramatic duty exposure, and others remain manageable but sensitive to classification accuracy. For procurement and supply chain leaders, 2025 has required a re-rating of total landed cost, supplier qualification, and nearshoring opportunities. U.S. enforcement and safety communications related to certain China-origin plastic syringes further amplify the case for diversified sourcing, with the FDA signaling adequate non-China capacity and encouraging transitions away from specific manufacturers. The result has been a measurable push to expand domestic and regional syringe production capacity, tightening lead times and improving supply assurance for critical care settings. An additional wrinkle is the evolving treatment of low-value direct-to-consumer shipments under the de minimis regime. Policy adjustments in 2025 have altered the calculus for small parcel imports from China, but medical supplies such as syringes and surgical gloves remain under strict duty regimes and safety scrutiny, limiting the relevance of de minimis workarounds for regulated healthcare products. Operationally, the key takeaway for single-use categories is to avoid overreliance on small-parcel channels to sidestep tariffs and to focus instead on compliant classification, country-of-origin shifts, and multi-region manufacturing partnerships. What matters most is proactive playmaking. Companies that have mapped their HTS exposure at the subheading level, validated alternate suppliers with robust quality systems, and secured dual-source film and connector options are entering 2026 with greater negotiating power and resilience. Those that delay will find themselves trading off margin and schedule flexibility, precisely as regulatory expectations for materials and documentation step up under USP <665>/<1665>. Segmentation insights reveal where value concentrates across products, materials, sterility, regulation, applications, end users, and distribution dynamics

Product architecture and use cases reveal where value is concentrating across the single-use ecosystem. Within product type, bioprocess containers continue to anchor upstream and downstream workflows, with media bags supporting buffer and media logistics, storage bags bridging cold and ambient holds, mixing bags underpinning high-throughput buffer prep, and bioreactor liners enabling rapid turnarounds in seed and production trains. Cell culture bags, spanning 2D formats for traditional adherent models and 3D formats for advanced cell therapy processes, are increasingly paired with perfusion-ready upstream strategies, which raises the bar for film characterization and closure integrity. In parallel, fluid management assemblies are evolving from commodity kits to engineered solutions; tubing sets are now specified alongside connectors, disconnectors, adapters, valves, and transfer sets to ensure sterility by design and minimize operator risk at line changeovers.

Filtration products are a second nucleus of differentiation. Capsule filters bring speed and ease-of-use for buffer and media prep, membrane filters remain the workhorses of clarification and sterile filtration, and chromatography devices translate into measurable productivity gains when paired with modern resins and modular skids. Sensors and probes have moved from peripheral components to quality-critical elements, with single-use pH and dissolved oxygen sensors reducing contamination risk and sterile cables enabling closed, disposable connectivity into control environments. Disposable labware and accessories-pipette tips, microplates, tubes, and sample bags-sustain the cadence of discovery and QC labs; their reliability affects throughput and data integrity as much as it does cost per experiment.

Material type is now a strategic choice. Plastics dominate for weight, flexibility, and sterilization compatibility, but silicone remains essential for tubing and elastomeric interfaces where flexibility and chemical resistance are critical. Glass continues to play a role where inertness and barrier properties are paramount, particularly in analytical workflows and specific storage needs. Selecting among these materials requires a risk-based approach to extractables and leachables, alignment with upcoming compendial expectations, and a pragmatic read of sterilization method availability.

Sterility preferences split the market into two distinct operating models. Sterile, ready-to-use assemblies compress validation and changeover time, supporting multiproduct plants and short clinical batches. Non-sterile components still fit controlled environments with strong in-house sterilization capabilities or where bespoke configurations require final assembly on site. Regulatory classification further stratifies offerings: Class I devices emphasize general controls and are prevalent in labware; Class II categories bring special controls and dominate where performance features and patient interface risks increase; Class III remains the province of devices where safety and efficacy must be proven in depth. As portfolios climb the regulatory ladder, design controls, quality documentation, and postmarket surveillance become core differentiators, not overhead.

Applications map the practical battlegrounds. Filtration remains ubiquitous across clarification and final fill; cell culture and mixing determine upstream yield and batch consistency; storage governs integrity across cold chains; sampling links to data integrity in PAT-rich facilities; in-vitro diagnostics demand precision consumables that do not confound assay performance; and surgical settings call for sterility, ergonomics, and proven reliability at point of care. Each application favors specific combinations of materials, sterilization status, and regulatory pathways.

End use diversifies demand patterns. Pharmaceutical and biopharmaceutical companies prioritize platform standardization and robust supplier SLAs; contract research organizations value configurability and lead time; academic and research institutes drive demand for smaller-lot labware and accessories; and original equipment manufacturers specify assemblies that integrate seamlessly with their skids and instruments. Distribution channels continue to bifurcate as well, with online platforms excelling at long-tail labware replenishment and offline channels retaining an edge where technical support, qualification services, and controlled storage are mission-critical.

Regional insights show divergent regulatory clocks, capacity footprints, and demand drivers across the Americas, EMEA, and Asia-Pacific bioprocess hubs

Regional dynamics shape how the single-use opportunity unfolds. In the Americas, policy and capacity developments are pulling in the same direction. Safety communications and enforcement actions around specific China-origin plastic syringes catalyzed a shift toward domestic and regional sourcing, and large suppliers have responded by increasing U.S. production. Within bioprocessing, new and expanded facilities-from large single-use container and fluid assembly sites in the Southeast to long-standing hubs in the Mountain West-are shortening lead times and enabling more localized qualification. Puerto Rico continues to play a pivotal role, with a deep manufacturing base for filters, single-use bags, and media serving the mainland efficiently and underpinning regional resilience. Across Europe, the momentum is equally strong, but the drivers emphasize sustainability, regulatory alignment, and in-region capacity. Climate-neutral life science manufacturing has moved from aspiration to execution, with new filtration sites designed to operate on renewable electricity and to recycle process water. Expanded distribution and down-filling centers are improving responsiveness across the continent, while the approaching effective dates for USP-linked plastic materials chapters and broader European standards create a compliance-first environment for cross-border supply. The net result is a network tuned for reliability and scope 3 reporting, with proximity to major biopharma clusters reducing logistics risk. In Asia-Pacific, demand remains diverse and fast-evolving. Mature markets continue to expand bioprocessing footprints, while emerging hubs are building capacity for clinical and early commercial supply. The region's manufacturing strengths in polymers and components remain critical to the global supply base, yet changing tariff landscapes and quality expectations are prompting more distributed strategies among global suppliers. At the same time, global manufacturers are balancing their Asia sourcing with investments in North America and Europe to offer customers a choice of origin, recognizing that modality mix and regulatory dossiers increasingly influence country-of-origin decisions for single-use systems.

Company strategies converge on capacity, portfolios, and sustainability as leaders scale single-use bags, filtration, analytics, and integrated assemblies

Corporate playbooks have converged on three themes: secure capacity, broaden portfolios, and operationalize sustainability. One cohort of leaders is expanding single-use container and fluid-handling capacity within the United States, underpinning "in-region for region" commitments while de-risking against tariff and logistics shocks. Recent openings and expansions in the Southeast and Mountain West illustrate how proximity can become a competitive advantage when lead time and changeover agility dominate customer priorities. Filtration and analytics are the second axis of competition. Merck's life science business has introduced a climate-neutral filtration manufacturing site in Ireland and expanded European distribution capabilities, signaling a dual commitment to capacity and sustainability. Meanwhile, strategic moves in the broader filtration and purification space-including announced acquisitions-highlight the importance of integrated offering breadth that spans capture, clarification, virus removal, and process monitoring. These shifts position suppliers to serve intensified and continuous processing strategies with end-to-end solutions. A third vector is platform innovation. Cytiva has extended its single-use bioreactor portfolio and advanced large-scale magnetic mixing systems, making it easier for manufacturers to standardize equipment trains while maintaining the flexibility required for novel modalities. These platform expansions are complemented by intensified upstream technologies from partners and specialists, enabling higher cell densities and more compact facilities. Other key players are reinforcing adjacent capabilities. Sartorius continues to enhance its North American footprint, with Puerto Rico serving as a cornerstone for bag, filter, and media capacity that supports U.S. demand. Avantor is emphasizing fluid-handling ecosystems and hydration solutions, aligning with customers' needs to integrate buffer prep seamlessly into single-use workflows. Repligen is pushing the frontier of process analytics and upstream intensification with next-generation at-line measurement and scalable cell retention systems, reflecting the heightened importance of PAT and closed-system processing. The through-line across these strategies is a move toward interoperable, data-rich portfolios that collapse changeover times and raise batch-to-batch consistency. Actionable priorities for leadership: de-risk supply, design for compliance, digitize quality, and align portfolios to high-growth therapeutic modalities

Senior leaders should prioritize four moves to convert today's shifts into durable advantage. First, re-engineer supply strategies around tariff-aware sourcing and dual qualification. Map SKUs to the HTS subheading level, quantify exposure under the latest Section 301 schedules, and execute controlled pilots with alternative origins for syringe-adjacent and sensor-rich categories. Build in supplier scorecards that weight quality-system maturity and compendial readiness alongside cost so that short-term savings do not translate into long-term regulatory friction.

Second, design for compliance now rather than later. With USP <665>/<1665> effective in May 2026 and <661.1>/<661.2> effective in December 2025, align internal and supplier documentation, extractables and leachables data packages, and change control processes. Prioritize standard films and connectors that already have robust data sets, and deploy a gap-closure plan for legacy assemblies. Where possible, choose components with clear roadmaps for meeting evolving expectations so that new filings will not be undermined by avoidable requalification.

Third, digitize quality at the point of use. Expand adoption of single-use pH and DO sensors with validated calibration approaches, integrate at-line and in-line analytics for real-time release strategies, and embed serialization or RFID where it improves inventory accuracy and CAPA traceability. Tie these changes to workforce enablement so that operators can act on data rather than merely collect it.

Fourth, balance standardization with targeted customization. Establish platform assemblies and bioprocess container families for 70-80% of use cases, while preserving a controlled path for bespoke configurations in cell therapy, viral vector production, and complex fill-finish. This approach preserves speed and cost discipline without constraining innovation. Across all four moves, communicate the sustainability narrative with specificity-energy sources, water reuse, and end-of-life options-because procurement, regulators, and investors increasingly ask for verifiable progress rather than broad commitments.

Methodology blends practitioner interviews, curated datasets, tariff schedules, standards tracking, and triangulated insights across the single-use value chain

This analysis synthesizes primary and secondary intelligence from across the single-use value chain. Primary research focused on structured interviews with procurement leads at pharmaceutical and biopharmaceutical manufacturers, operations heads at contract research organizations, and quality and regulatory specialists at original equipment manufacturers. Discussions explored the decision criteria for platform standardization, the practical status of extractables and leachables programs, the pace of single-use sensor adoption, and the operational response to new tariff schedules.

Secondary research integrated the most authoritative public sources and technical publications available. For policy and compliance, we examined the final Section 301 tariff modifications and effective dates, cross-referencing multiple legal and policy analyses to confirm rate changes and timing. For regulatory standards, we tracked USP's official schedules for <665>, <1665>, <661.1>, and <661.2>, as well as practitioner articles that interpret readiness actions. Safety communications from regulators on specific device categories, including plastic syringes, were reviewed to gauge their practical impact on sourcing and quality oversight.

Company developments were documented through corporate press releases, specialty industry outlets, and filings, paying special attention to capacity additions, product platform extensions, and announced transactions that reshape the competitive landscape. We complemented these sources with trade and technical media to understand how new systems-such as large-scale magnetic mixers and expanded single-use bioreactors-are adopted on the plant floor. All statements of fact in this summary are anchored to the cited sources, while forward-looking implications derive from triangulated patterns observed across interviews and published data. Conclusion underscores a decisive shift toward standardized yet flexible systems where compliance, speed, and sustainability determine competitive advantage

The single-use consumables market is no longer defined by convenience or incremental cost savings. It is a critical enabler of agile manufacturing, an anchor for contamination control, and a proving ground for digital analytics embedded at the point of use. In 2025, the operational rulebook changed in two important ways: tariff exposure became a design parameter that must be managed proactively, and compendial expectations for plastics used in manufacturing took a clear step toward enforceable, risk-based qualification. Together, those shifts move the conversation from "Can single-use match stainless?" to "How do we instrument and document single-use so that it accelerates compliance and scale?"

Leadership teams that internalize these changes will unlock faster tech transfers, smoother scale-up from clinic to commercial, and more resilient cost structures. The practical path is straightforward, if demanding: qualify dual origins for high-exposure SKUs, use platform assemblies with well-characterized films and connectors, adopt smart sensors and analytics where they advance parametric control, and invest in the documentation and partnerships required for upcoming USP timelines. With that foundation, single-use portfolios will not merely keep pace; they will set the standard for the next decade of bioprocess and diagnostic excellence.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Single Use Consumables Market, by Product Type

• 8.1. Bioprocess Containers
  • 8.1.1. Media Bags
  • 8.1.2. Storage Bags
  • 8.1.3. Mixing Bags
  • 8.1.4. Cell Culture Bags
    • 8.1.4.1. 2D
    • 8.1.4.2. 3D
• 8.2. Fluid Management Assemblies
  • 8.2.1. Tubing Sets
  • 8.2.2. Connectors, Disconnectors, & Adapters
  • 8.2.3. Valves
  • 8.2.4. Transfer Sets
• 8.3. Filtration Products
  • 8.3.1. Capsule Filters
  • 8.3.2. Membrane Filters
  • 8.3.3. Chromatography Devices
• 8.4. Sensors & Probes
  • 8.4.1. pH Sensors
  • 8.4.2. DO Sensors
  • 8.4.3. Sterile Cables
• 8.5. Labware & Accessories
  • 8.5.1. Pipette Tips
  • 8.5.2. Microplates
  • 8.5.3. Tubes
  • 8.5.4. Sample Bags

9. Single Use Consumables Market, by Material Type

• 9.1. Glass
• 9.2. Plastics
• 9.3. Silicone

10. Single Use Consumables Market, by Material Form

• 10.1. Films
• 10.2. Sheet
• 10.3. Non-Woven
• 10.4. Membrane
• 10.5. Foils
• 10.6. Tubing

11. Single Use Consumables Market, by Sterility

• 11.1. Sterile
• 11.2. Non Sterile

12. Single Use Consumables Market, by Regulatory Classification

• 12.1. Class I
• 12.2. Class II
• 12.3. Class III

13. Single Use Consumables Market, by Application

• 13.1. Filtration
• 13.2. Cell Culture & Mixing
• 13.3. Storage
• 13.4. Sampling
• 13.5. In-Vitro Diagnostics
• 13.6. Surgery

14. Single Use Consumables Market, by End Use

• 14.1. Pharmaceutical & Biopharmaceutical Companies
• 14.2. Contract Research Organizations
• 14.3. Academic & Research Institutes
• 14.4. Original Equipment Manufacturers (OEMs)

15. Single Use Consumables Market, by Distribution Channel

• 15.1. Online
• 15.2. Offline

16. Single Use Consumables Market, by Region

• 16.1. Americas
  • 16.1.1. North America
  • 16.1.2. Latin America
• 16.2. Europe, Middle East & Africa
  • 16.2.1. Europe
  • 16.2.2. Middle East
  • 16.2.3. Africa
• 16.3. Asia-Pacific

17. Single Use Consumables Market, by Group

• 17.1. ASEAN
• 17.2. GCC
• 17.3. European Union
• 17.4. BRICS
• 17.5. G7
• 17.6. NATO

18. Single Use Consumables Market, by Country

• 18.1. United States
• 18.2. Canada
• 18.3. Mexico
• 18.4. Brazil
• 18.5. United Kingdom
• 18.6. Germany
• 18.7. France
• 18.8. Russia
• 18.9. Italy
• 18.10. Spain
• 18.11. China
• 18.12. India
• 18.13. Japan
• 18.14. Australia
• 18.15. South Korea

19. United States Single Use Consumables Market

20. China Single Use Consumables Market

21. Competitive Landscape

• 21.1. Market Concentration Analysis, 2025
  • 21.1.1. Concentration Ratio (CR)
  • 21.1.2. Herfindahl Hirschman Index (HHI)
• 21.2. Recent Developments & Impact Analysis, 2025
• 21.3. Product Portfolio Analysis, 2025
• 21.4. Benchmarking Analysis, 2025
• 21.5. 3M Company
• 21.6. Adolf Kuhner AG
• 21.7. Avantor, Inc.
• 21.8. Boehringer Ingelheim International GmbH
• 21.9. Broadley-James Corporation
• 21.10. Cellexus Limited
• 21.11. Cesco Bioengineering Co., Ltd.
• 21.12. Colder Products Company by Dover Corporation
• 21.13. Compagnie de Saint-Gobain
• 21.14. Corning Incorporated
• 21.15. Danaher Corporation
• 21.16. Distek, Inc.
• 21.17. Entegris, Inc.
• 21.18. Eppendorf SE
• 21.19. ESI Technologies
• 21.20. GEMU Gebr. Muller Apparatebau GmbH & Co. KG
• 21.21. Getinge AB
• 21.22. Hamilton Company
• 21.23. Infors AG
• 21.24. Lonza Group Ltd.
• 21.25. Meissner Filtration Products, Inc.
• 21.26. Merck KGaA
• 21.27. METTLER TOLEDO
• 21.28. NewAge Industries, Inc.
• 21.29. Parker Hannifin Corporation
• 21.30. PBS Biotech, Inc.
• 21.31. PreSens Precision Sensing GmbH
• 21.32. Rentschler Biopharma SE
• 21.33. Repligen Corporation
• 21.34. Sartorius AG
• 21.35. Sentinel Process Systems Inc.
• 21.36. Sterlitech Corporation
• 21.37. Thermo Fisher Scientific Inc.
• 21.38. Venair Iberica SAU